International Research Journal of Education and Technology

Peer Reviewed Journal, **ISSN 2581-7795**

Beyond Menopause: Navigating Physical, Emotional, and Social Transitions

Shalini Dubey, Research Scholar, Malwanchal University, Indore

Dr Jomet George, Research Supervisor, Malwanchal University, Indore

Abstract

Menopause marks the end of spontaneous ovarian function, but “post-menopause” is not an end point—it's a long life stage with evolving physical, emotional, and social dynamics. This article synthesizes current guidance and evidence to help readers understand what typically changes after the final menstrual period and how to navigate those changes with confidence. We review common physical concerns (vasomotor symptoms, sleep disruption, weight and body-composition shifts, cardiometabolic risk, bone health, and urogenital changes), summarize treatment options—including menopausal hormone therapy (MHT), FDA-approved nonhormonal therapies, and behavioral or lifestyle strategies—and clarify where major guidelines agree or diverge. Emotional health receives specific attention, with an emphasis on mood vulnerability in the menopausal transition and practical steps for resilience in later post-menopause. Finally, we explore social transitions: evolving identities, intimacy and sexuality, caregiving, work and retirement, and financial/household restructuring. Throughout, we translate high-quality guidance from professional societies and U.S. regulatory bodies into plain-language, actionable advice, while noting safety caveats (e.g., liver monitoring for the nonhormonal hot-flash medication fezolinetant). The goal is a realistic, reassuring roadmap: many post-menopausal changes are manageable—and often improvable—when people combine evidence-based treatments with sustained attention to heart, bone, brain, and relationship health. (The Menopause Society [NAMS], 2022; NAMS, 2023; U.S. Food and Drug Administration [FDA], 2023, 2024; U.S. Preventive Services Task Force [USPSTF], 2022, 2025; El Khoudary et al., 2020; Parish et al., 2020; Badawy et al., 2024; National Institutes of Health Office of Dietary Supplements [NIH ODS], 2025). (The Menopause Society, UW Departments, U.S. Food and Drug Administration, USPSTF, JAMA Network, AHA Journals, PubMed, Office of Dietary Supplements)

Introduction: Post-menopause as a life stage

After 12 consecutive months without a period, a person is considered post-menopausal. The body stabilizes at a new hormonal baseline in the years that follow, yet symptoms may persist or evolve (e.g., hot flashes can last years, and genitourinary symptoms often progress). Clinically, this spans medical domains: cardiovascular prevention, bone protection, sexual health, mental health, and sleep. Contemporary guidance emphasizes individualized decisions—especially for symptom therapy and chronic-disease prevention. (NAMS, 2022; NAMS, 2023; USPSTF, 2022). (The Menopause Society, UW Departments, USPSTF)

Physical transitions

Vasomotor symptoms (VMS) and sleep

Hot flashes and night sweats are the hallmark complaints; they are most common around the transition but can persist into post-menopause for many. MHT remains the most effective therapy for VMS in appropriately selected candidates (generally <60 years or within 10 years of menopause, without contraindications). Evidence-based nonhormonal options include SSRIs/SNRIs, gabapentin, the NK3-receptor antagonist fezolinetant, cognitive-behavioral therapy (CBT) and clinical hypnosis; oxybutynin has supportive evidence as well. (NAMS, 2022; NAMS, 2023). (The Menopause Society, UW Departments)

Fezolinetant safety note. In May 2023 the FDA approved fezolinetant for moderate-to-severe VMS. In late 2024, the FDA strengthened labeling with a boxed warning about rare but serious liver injury and advised baseline and periodic liver-function monitoring early in therapy. This doesn't negate efficacy, but it changes the monitoring conversation for those choosing a nonhormonal medication. (FDA, 2023; FDA, 2024). (U.S. Food and Drug Administration)

Sleep and VMS interplay. Night sweats fragment sleep; CBT-I (insomnia-focused CBT) and CBT targeted to hot-flash coping can reduce symptom "bothersomeness" and improve sleep quality; gabapentin at bedtime can also help some. (NAMS, 2023). (UW Departments)

Weight, body composition, and metabolism

Post-menopause is associated with a shift toward central adiposity and modest declines in lean mass, which contribute to insulin resistance and adverse lipid changes. While aging itself drives much of the trajectory, the menopause transition is a period of cardiometabolic risk acceleration in many women, supporting an early-prevention focus on activity, nutrition quality, sleep, and tobacco avoidance. (El Khoudary et al., 2020). (AHA Journals)

Cardiovascular health

Cardiovascular disease (CVD) remains the leading cause of death in women. The AHA scientific statement identifies the menopause transition and early post-menopause as a window when risk factors (LDL-C, visceral fat, vascular stiffness) often worsen, underscoring the value of lifestyle interventions, blood-pressure and lipid surveillance, and treatment when indicated. MHT should **not** be started to prevent CVD; timing matters mostly for symptom benefit and risk balance. (El Khoudary et al., 2020; USPSTF, 2022). (AHA Journals, USPSTF)

Practical checks: know your numbers (BP, A1c/glucose, fasting lipid panel), move most days (aerobic + resistance), prioritize sleep, minimize alcohol, and don't smoke. These fundamentals often outperform any supplement stack in long-term risk reduction. (El Khoudary et al., 2020). (AHA Journals)

Bone health

Estrogen decline accelerates bone turnover, raising fracture risk. USPSTF (January 14, 2025) recommends osteoporosis screening with DXA for **all women ≥65**, and for **post-menopausal women <65** with ≥1 risk factor and elevated calculated risk; men remain an "I statement." Treatment decisions should integrate clinical risk, BMD, and patient values. (USPSTF, 2025). (JAMA Network)

Everyday bone protectors. Ensure adequate calcium and vitamin D (typical targets for post-menopausal adults: ~1,200 mg/day calcium from diet + supplements as needed; 800–1,000 IU/day vitamin D, individualized to blood levels), perform regular resistance and weight-bearing exercise, and address fall risk at home. (NIH ODS, 2025). (Office of Dietary Supplements)

Genitourinary & sexual health

Genitourinary syndrome of menopause (GSM)—vaginal dryness, dyspareunia, irritation; urinary urgency, frequency, recurrent UTI—often **progresses** with time if untreated. Evidence-based options include nonprescription moisturizers/lubricants; low-dose vaginal estrogen (with minimal systemic absorption); vaginal DHEA (prasterone); and the SERM ospemifene for dyspareunia. Therapy selection is individualized (e.g., prior breast cancer, preferences). (Parish et al., 2020; NAMS, 2022). (The Menopause Society)

Emotional and cognitive wellbeing

Mood

Risk of **new or recurrent depression** increases during the **menopausal transition**, driven by fluctuating hormones, sleep disturbance, stressors, and life events. A 2024 meta-analysis of prospective cohorts found perimenopausal women had ~40% higher odds of depressive symptoms/diagnoses vs. premenopausal women; importantly, **post-menopausal** status did *not* show a significantly elevated risk compared with premenopause, suggesting vulnerability peaks earlier. Still, some individuals do experience persistent or late-emerging depression that warrants standard care. (Badawy et al., 2024). (PubMed)

What helps: screen (PHQ-9/GAD-7), treat sleep problems, consider psychotherapy (CBT or interpersonal therapy), and use antidepressants when indicated; if VMS or GSM exacerbate mood or intimacy distress, treat those too. For selected symptomatic patients in early menopause, MHT may indirectly improve mood via VMS relief but is **not** a primary antidepressant. (NAMS, 2023; NAMS, 2022). (UW Departments, The Menopause Society)

Cognition ("brain fog")

Transient word-finding or concentration complaints are common; they often improve as sleep and VMS improve. MHT is **not recommended** to prevent dementia; decisions about hormone therapy should center on symptom relief and short-term quality of life, not cognitive disease prevention. (NAMS, 2022; USPSTF, 2022). (The Menopause Society, USPSTF)

Treatment decisions: What the major guidelines say (and don't)

1. **Menopausal hormone therapy (MHT).**
   - **Most effective** for VMS and helpful for GSM prevention/treatment; it **prevents bone loss and fractures** while taken. Risk varies by formulation, dose, route, and timing; transdermal estradiol and lower doses may reduce thrombotic risk for some. Use a progestogen if the uterus is present. Reassess benefits/risks periodically; there's **no automatic age to stop** if benefits continue and risks remain acceptable. (NAMS, 2022). (The Menopause Society)
   - **Not for primary prevention** of chronic conditions (e.g., CVD, dementia) in asymptomatic people. (USPSTF, 2022). (USPSTF)
2. **Evidence-based nonhormonal therapies for VMS.**
   - SSRIs/SNRIs, gabapentin, **fezolinetant** (with liver-function monitoring), and behavioral therapies (CBT for VMS and CBT-I for co-morbid insomnia) have supportive evidence. (NAMS, 2023; FDA, 2023, 2024). (UW Departments, U.S. Food and Drug Administration)
3. **GSM options.**
   - First-line nonprescription moisturizers/lubricants; if insufficient, consider low-dose vaginal estrogen, DHEA, or ospemifene; pelvic-floor therapy can help urinary symptoms. (Parish et al., 2020; NAMS, 2022). (The Menopause Society)
4. **Bone protection and screening.**
   - **Screen** as per 2025 USPSTF; address calcium/vitamin D, movement, and fall prevention; treat osteoporosis when criteria are met. (USPSTF, 2025; NIH ODS, 2025). (JAMA Network, Office of Dietary Supplements)
5. **Cardiometabolic prevention.**
   - Midlife is a **window** for weight, lipid, and glucose trajectories to worsen; adopt early prevention and treat risk factors per standard primary-prevention guidelines. (El Khoudary et al., 2020). (AHA Journals)

Social transitions: identity, intimacy, work, and community

Post-menopause often coincides with meaningful life changes—children leaving home, caregiving for elders, career pivots, or retirement. It can also be a period of renewed agency and clarity about priorities. A few evidence-informed, practical angles:

- **Intimacy & sexuality.** Normalize conversations about desire changes, pain, and arousal. Treat GSM to reduce pain and urinary symptoms that undermine intimacy; consider sex therapy for mismatched desire or performance anxiety. (Parish et al., 2020).
- **Work & purpose.** If symptoms disrupt work (e.g., sleep loss from VMS), treat symptoms and trial small environmental tweaks—layered clothing, access to cool air,

flexible breaks, hydration, and consistent sleep-wake times. Evidence-based symptom control often restores performance. (NAMS, 2023). (UW Departments)

- **Caregiving & boundaries.** Many midlife adults juggle multigenerational care. Shared calendars, explicit division of labor, and deliberate respite lower burnout; protecting exercise and sleep blocks is protective for mood and heart health. (El Khoudary et al., 2020; Badawy et al., 2024). (AHA Journals, PubMed)

A practical action plan (evidence-guided)

1. **Map your symptoms & priorities.** What bothers you most—hot flashes, sleep, pain with sex, brain fog, mood, or bladder symptoms? This clarifies whether to start with MHT, a nonhormonal VMS option, GSM therapy, CBT-I, or mood treatment. (NAMS, 2022; NAMS, 2023). (The Menopause Society, UW Departments)
2. **Know your numbers, annually.** BP, lipids, A1c (or fasting glucose), weight/waist, and—if at risk—kidney and liver panels (the latter is essential if taking **fezolinetant**). (El Khoudary et al., 2020; FDA, 2024). (AHA Journals, U.S. Food and Drug Administration)
3. **Screen your bones on time.** DXA at 65+ (earlier if risk factors). Address calcium (≈1,200 mg/day total) and vitamin D (≈800–1,000 IU/day) targets unless your clinician personalizes them based on labs/conditions. (USPSTF, 2025; NIH ODS, 2025). (JAMA Network, Office of Dietary Supplements)
4. **Move most days.** Mix aerobic activity with resistance training; add balance work to prevent falls. Training helps VMS tolerance, preserves bone and muscle, and trims cardiometabolic risk. (El Khoudary et al., 2020). (AHA Journals)
5. **Sleep like it's your job.** Treat VMS; consider CBT-I; keep a consistent schedule; minimize alcohol (especially near bedtime). (NAMS, 2023). (UW Departments)
6. **Invest in relationships.** Plan for intimacy (and treat GSM), cultivate social connection, and renegotiate roles at home as life evolves. (Parish et al., 2020).
7. **Revisit decisions periodically.** Symptom intensity and risk profiles change. Re-assess MHT or nonhormonal regimens, bone strategy, and CVD risk each year. (NAMS, 2022; USPSTF, 2025). (The Menopause Society, JAMA Network)

Conclusion

Life after the final menstrual period is neither a decline nor a diagnosis—it's a stage with its own physiology and possibilities. A pragmatic combination of **symptom-targeted therapies** (hormonal or nonhormonal), **prevention habits** (movement, sleep, nutrition, tobacco avoidance), **screening on time** (DXA and cardiometabolic checks), and **attention to relationships and purpose** yields the best long-term outcomes. When in doubt, anchor decisions to your most bothersome symptoms and your personal values, and use shared decision-making with a clinician who's comfortable with midlife health. Most importantly, expect improvement: with appropriate treatment and support, quality of life in post-menopause

can be robust and deeply fulfilling. (NAMS, 2022; NAMS, 2023; USPSTF, 2025; El Khoudary et al., 2020). (The Menopause Society, UW Departments, JAMA Network, AHA Journals)

References

Badawy, Y., Spector, A., Li, Z., & Desai, R. (2024). **The risk of depression in the menopausal stages: A systematic review and meta-analysis.** *Journal of Affective Disorders, 358*, 1–12. https://pubmed.ncbi.nlm.nih.gov/38642901/ (PubMed)

El Khoudary, S. R., Santoro, N., Chen, H. Y., Tepper, P. G., Brooks, M. M., Thurston, R. C., … & Wenger, N. K. (2020). **Menopause transition and cardiovascular disease risk: Implications for timing of early prevention.** *Circulation, 142*(25), e506–e532. https://www.ahajournals.org/doi/pdf/10.1161/CIR.0000000000000912 (AHA Journals)

National Institutes of Health, Office of Dietary Supplements. (2025, July 11). **Calcium—Health professional fact sheet.** https://ods.od.nih.gov/factsheets/Calcium-HealthProfessional/ (Office of Dietary Supplements)

Parish, S. J., Nappi, R. E., Krychman, M. L., Kellogg-Spadt, S., Simon, J. A., Goldstein, J. A., … & Waldbaum, A. S. (2020). **The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society and The International Society for the Study of Women's Sexual Health.** *Menopause*, *27*(9), 976–992. (Position statement PDF). https://www.isswsh.org/images/content/2020-NAMS-GSM-Paper.pdf

The Menopause Society (North American Menopause Society). (2022). **The 2022 hormone therapy position statement of The North American Menopause Society.** *Menopause*, *29*(7), 767–794. https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdf (The Menopause Society)

The North American Menopause Society 2023 Nonhormone Therapy Position Statement Advisory Panel. (2023). **Nonhormone therapy for menopause-associated vasomotor symptoms: 2023 position statement of The North American Menopause Society.** *Menopause*, *30*(6), 573–590. (Author manuscript PDF). https://depts.washington.edu/mbwc/content/page-files/NAMS_2023-nonhormone-therapy-position-statement_%281%2922.pdf (UW Departments)

U.S. Food and Drug Administration. (2023, May 12). **FDA approves novel drug to treat moderate to severe hot flashes caused by menopause** (Veozah/fezolinetant). https://www.fda.gov/news-events/press-announcements/fda-approves-novel-drug-treat-moderate-severe-hot-flashes-caused-menopause (U.S. Food and Drug Administration)

U.S. Food and Drug Administration. (2024, December 20). **FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause**—Drug Safety Communication (boxed warning and monitoring). https://www.fda.gov/drugs/drug-safety-and-availability/fda-adds-warning-about-rare-

occurrence-serious-liver-injury-use-veozah-fezolinetant-hot-flashes-due (U.S. Food and Drug Administration)

U.S. Preventive Services Task Force. (2022). **Hormone therapy in postmenopausal persons: Primary prevention of chronic conditions** (Final recommendation statement). https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/menopausal-hormone-therapy-preventive-medication (USPSTF)

U.S. Preventive Services Task Force; Nicholson, W. K., et al. (2025, January 14). **Screening for osteoporosis to prevent fractures: US Preventive Services Task Force recommendation statement.** *JAMA.* https://jamanetwork.com/journals/jama/fullarticle/2829238 (JAMA Network)